Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	9.43	18.44	32.17
Revenue Growth (YoY)	-	-	-48.83%	-42.68%	371.02%
Cost of Revenue	210.39	167.51	105.77	75.46	50.52
Gross Profit	-210.39	-167.51	-96.33	-57.03	-18.36
Selling, General & Admin	68.9	46.54	32.81	21.97	12.94
Operating Expenses	68.9	46.54	32.81	21.97	12.94
Operating Income	-279.3	-214.05	-129.14	-78.99	-31.3
Interest Expense	-	-	-	-	-0.48
Interest & Investment Income	41.94	27.62	8.71	0.47	2.28
Currency Exchange Gain (Loss)	-1.06	0.2	-1.89	0.36	1.4
EBT Excluding Unusual Items	-238.42	-186.24	-122.32	-78.17	-28.11
Gain (Loss) on Sale of Investments	-	3.55	-2.93	-0.72	0
Other Unusual Items	-	-	-	-	-0.99
Pretax Income	-238.42	-182.69	-125.26	-78.89	-29.09
Income Tax Expense	-4.09	-0.29	0.12	-0.01	-0.26
Net Income	-234.33	-182.39	-125.37	-78.88	-28.84
Preferred Dividends & Other Adjustments	-	-	-0.44	-1.8	-
Net Income to Common	-234.33	-182.39	-124.94	-77.09	-28.84
Shares Outstanding (Basic)	78	67	61	44	36
Shares Outstanding (Diluted)	78	67	61	44	36
Shares Change (YoY)	16.45%	10.48%	38.77%	21.09%	23.57%
EPS (Basic)	-3.01	-2.73	-2.06	-1.77	-0.80
EPS (Diluted)	-3.01	-2.73	-2.06	-1.77	-0.80
Free Cash Flow	-184.46	-156.73	-103.92	-71.55	-50.76
Free Cash Flow Per Share	-2.37	-2.34	-1.72	-1.64	-1.41
Gross Margin	-	-	-	-	-57.07%
Operating Margin	-	-	-1368.91%	-428.45%	-97.31%
Profit Margin	-	-	-1324.32%	-418.11%	-89.65%
Free Cash Flow Margin	-	-	-1101.57%	-388.09%	-157.81%
EBITDA	-276.74	-211.99	-127.74	-78.09	-30.66
EBITDA Margin	-	-	-	-	-95.31%
D&A For EBITDA	2.56	2.06	1.41	0.91	0.64
EBIT	-279.3	-214.05	-129.14	-78.99	-31.3
EBIT Margin	-	-	-	-	-97.31%

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q